115 related articles for article (PubMed ID: 38546079)
1. Evaluation of the Cutoff Point and Diagnostic Value of the Neutrophil-to-Lymphocyte Ratio in Predicting Ovarian Cancer Compared to Pathological Findings.
Hosseini MS; Amiri F; Rezapour M; Ashraf Ganjoie T; Farzaneh F; Arab M; Talayeh M; Beheshti Rooy R; Hadi F
Asian Pac J Cancer Prev; 2024 Mar; 25(3):971-976. PubMed ID: 38546079
[TBL] [Abstract][Full Text] [Related]
2. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of serum D-dimer, CA125, and neutrophil-to-lymphocyte ratio in differentiating ovarian cancer and endometriosis.
Chen L; Wang X; Shu J; Xu S; Wu Q; Yu Y
Int J Gynaecol Obstet; 2019 Nov; 147(2):212-218. PubMed ID: 31469423
[TBL] [Abstract][Full Text] [Related]
5. Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors.
Huang K; Xu S; Wang J; Ge L; Xu J; Jia X
J Ovarian Res; 2023 Feb; 16(1):37. PubMed ID: 36759870
[TBL] [Abstract][Full Text] [Related]
6. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor.
Seckin KD; Karslı MF; Yucel B; Bestel M; Yıldırım D; Canaz E; Akbayır O
Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():60-3. PubMed ID: 26683535
[TBL] [Abstract][Full Text] [Related]
7. Comparison of neutrophil/lymphocyte and platelet/ lymphocyte ratios for predicting malignant potential of suspicious ovarian masses in gynecology practice.
Topcu HO; Guzel AI; Ozer I; Kokanali MK; Gokturk U; Muftuoglu KH; Doganay M
Asian Pac J Cancer Prev; 2014; 15(15):6239-41. PubMed ID: 25124604
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion.
Polat M; Senol T; Ozkaya E; Ogurlu Pakay G; Cikman MS; Konukcu B; Ozten MA; Karateke A
Clin Transl Oncol; 2016 May; 18(5):457-63. PubMed ID: 26289552
[TBL] [Abstract][Full Text] [Related]
11. Differential blood count as triage tool in evaluation of pelvic masses.
Cramer DW; Benjamin Iv WJ; Vitonis AF; Berkowitz R; Goodman A; Matulonis U
Int J Gynecol Cancer; 2021 May; 31(5):733-743. PubMed ID: 32487682
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K
Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
[TBL] [Abstract][Full Text] [Related]
14. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
Wang Z; Tao X; Ying C
Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
[TBL] [Abstract][Full Text] [Related]
15. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
[TBL] [Abstract][Full Text] [Related]
16. The performance of Carbohydrate Antigen 125-Thomsen-nouveau and anti-Müllerian hormone combined with CA125, Human epididymis protein 4 and Risk of Malignancy Algorithm in diagnosis for patients with Epithelial ovarian cancer.
Hou X; Liu S; Liu J; Zhou J; Liang Y; Cui L
Clin Biochem; 2023 Sep; 119():110615. PubMed ID: 37517433
[TBL] [Abstract][Full Text] [Related]
17. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical utility between neutrophil count and neutrophil-lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review.
Komura N; Mabuchi S; Yokoi E; Kozasa K; Kuroda H; Sasano T; Matsumoto Y; Kimura T
Int J Clin Oncol; 2018 Feb; 23(1):104-113. PubMed ID: 28951992
[TBL] [Abstract][Full Text] [Related]
19. Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer.
Li Z; Hong N; Robertson M; Wang C; Jiang G
Sci Rep; 2017 Feb; 7():43001. PubMed ID: 28223716
[TBL] [Abstract][Full Text] [Related]
20. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
